Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: October 2, 2005 (Nine-month period ended October 2, 2005)
Business Overview: Illumina develops and markets tools for large-scale analysis of genetic variation and function, including oligonucleotides, genotyping systems (BeadLab, BeadStation), and gene expression systems. The company operates in the life sciences and pharmaceutical sectors.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Oct 2, 2005 | Nine Months Ended Oct 2, 2005 | Nine Months Ended Oct 3, 2004 |
|---|---|---|---|
| Total Revenue | $19,516 | $50,488 | $35,800 |
| Net Loss | $(1,426) | $(21,200) | $(9,472) |
| Loss per Share (Basic/Diluted) | $(0.03) | $(0.53) | $(0.27) |
| Cash and Cash Equivalents | $50,172 (Oct 2, 2005) | N/A | |
| Net Cash Used in Operating Activities | N/A | $(11,088) | $(21,434) |
| Stockholders' Equity | $71,104 (Oct 2, 2005) | N/A |
Margins (Nine Months Ended Oct 2, 2005):
- Gross Margin on Product Revenue: 66% (down from 72% in prior year)
- Gross Margin on Service Revenue: 74% (down from 80% in prior year)
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 41% year-over-year for the nine-month period ($50.5M vs. $35.8M). Product revenue grew 37% and service revenue grew 103%.
- Increased Net Loss: Net loss widened significantly to $21.2M for the nine months ended Oct 2, 2005, compared to $9.5M in the prior year period. This was primarily driven by a one-time non-cash charge of $15.8M for acquired in-process research and development (IPR&D) related to the CyVera acquisition.
- Acquisition Impact: On April 8, 2005, Illumina acquired CyVera Corporation for approximately $17.8M. The acquisition added $2.3M in goodwill and $15.8M in IPR&D (expensed immediately).
- Litigation Resolution: A $5.9M liability related to a termination-of-employment lawsuit was paid in January 2005, removing the liability from the balance sheet. In the prior year period, the company recorded a $3.3M gain due to a reduction in this judgment.
- Expense Trends: R&D expenses increased 28% year-over-year ($20.2M vs. $15.9M) due to development costs for CyVera technology. SG&A expenses remained relatively flat ($19.8M vs. $19.3M) despite increased sales and marketing personnel costs, offset by lower legal fees.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management expects current cash and investments ($50.2M) to fund operations for at least 24 months.
- The company anticipates continued net losses in 2005 due to significant R&D, manufacturing scale-up, and sales infrastructure costs.
- Adoption of SFAS 123R (Share-Based Payment) in 2006 is expected to result in significant non-cash charges to operating expenses, though it will not impact cash flows.
- First products based on CyVera technology are expected in the second half of 2006.
Key Risks and Contingencies:
- Legal Proceedings: Active litigation with Affymetrix regarding patent infringement of BeadArray products (trial scheduled for Oct 2006). A new lawsuit filed by Dr. Anthony Czarnik alleges fraudulent omission of inventorship on patents.
- Market Competition: Intense competition from companies like Affymetrix; risk of technology obsolescence or price reductions.
- Revenue Volatility: Revenue is subject to fluctuations due to the timing of high-value product sales and government grants (e.g., International HapMap Project revenue was largely completed in Q1 2005).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $50.2M cash balance against projected burn rates, considering the expectation of continued losses.
- Acquisition Integration: Assess the progress of integrating CyVera's microbead technology and the timeline for commercial product launch (expected H2 2006).
- Legal Exposure: Monitor the status of the Affymetrix patent infringement suit and the Dr. Czarnik inventorship claim, as adverse outcomes could restrict product sales or incur significant damages.
- Revenue Mix: Analyze the shift in revenue sources following the completion of the International HapMap Project grant and the reliance on third-party service contracts.
- Accounting Changes: Review the impact of the upcoming adoption of SFAS 123R on future reported earnings and stock-based compensation expenses.